Kineret Related Published Studies
Well-designed clinical trials related to Kineret (Anakinra)
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. [2006.08]
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. [2004.09]
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. [2004.06]
Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. [2004.06]
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. [2004.05]
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. [2004.04]
Pharmacokinetics of anakinra in subjects with different levels of renal function. [2003.07]
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. [2003.04]
Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. [2003.02]
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. [2002.11]
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. [2002.03]
Well-designed clinical trials possibly related to Kineret (Anakinra)
Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. [2008.07]
Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone. [2008.07]
Duration and severity of symptoms and levels of plasma interleukin-1 receptor antagonist, soluble tumor necrosis factor receptor, and adhesion molecules in patients with common cold treated with zinc acetate. [2008.03.15]
Effect of weight loss on cytokine messenger RNA expression in peripheral blood mononuclear cells of obese subjects with the metabolic syndrome. [2008.02]
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2008.01]
Inflammation a possible link between economical stress and coronary heart disease. [2008]
Can the interleukin-1 receptor antagonist (IL-1ra) be a marker of anti-inflammatory response to enteral immunonutrition in malnourished patients after pancreaticoduodenectomy? [2007.11.09]
Quercetin's influence on exercise-induced changes in plasma cytokines and muscle and leukocyte cytokine mRNA. [2007.11]
Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. [2007.08.01]
Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. [2007.06.15]
Effect of blockade of TNF-alpha and interleukin-1 action on bone resorption in early postmenopausal women. [2007.05]
Interleukin-1-receptor antagonist in type 2 diabetes mellitus. [2007.04.12]
Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. [2007.03]
Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different gene-polymorphisms of proinflammatory cytokines. [2007.01]
Exhaustion is associated with low macrophage migration inhibitory factor expression in patients with coronary artery disease. [2007.01]
Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study. [2007.01]
Effect of meloxicam on gingival crevicular fluid IL-1beta and IL1 receptor antagonist levels in subjects with chronic periodontitis, and its effects on clinical parameters. [2006.12]
Serum IL-6 and IL-1-ra with sequential organ failure assessment scores in septic patients receiving high-volume haemofiltration and continuous venovenous haemofiltration. [2006.10]
[Targeted anti-cytokine therapies for osteoarthritis] [2006.10]
Blood leukocyte mRNA expression for IL-10, IL-1Ra, and IL-8, but not IL-6, increases after exercise. [2006.09]
Effects of sevoflurane on cytokine balance in patients undergoing coronary artery bypass graft surgery. [2006.08]
Self-rated health and vital exhaustion, but not depression, is related to inflammation in women with coronary heart disease. [2005.11]
Evidence of a pharmacogenomic response to interleukin-l receptor antagonist in rheumatoid arthritis. [2005.09]
Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. [2005.07]
Acute inflammation and negative mood: mediation by cytokine activation. [2005.07]
Inflammatory response in children after laparoscopic vs open Nissen fundoplication: randomized controlled trial. [2005.06]
Modulation of clinical expression of plaque-induced gingivitis: interleukin-1 gene cluster polymorphisms. [2005.01]
Methylprednisolone favourably alters plasma and urinary cytokine homeostasis and subclinical renal injury at cardiac surgery. [2004.07.21]
Supplementation with vitamins C and E inhibits the release of interleukin-6 from contracting human skeletal muscle. [2004.07.15]
Lefunomide in combination therapy. [2004.06]
The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery. [2004.02]
[IL-1Ra (recombinant human IL-1 receptor antagonist) in the treatment of rheumatoid arthritis: the efficacy] [2004.01]
Decreased interleukin-1 receptor antagonist response following moderate exercise in patients with colorectal carcinoma after primary treatment. [2004]
Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. [2004]
Cytokines in periradicular lesions: the effect of linezolid treatment. [2003.10]
Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. [2003.10]
Effects of plaque, psychological stress and gender on crevicular Il-1beta and Il-1ra secretion. [2003.03]
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. [2002.11.15]
Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. [2002.06.04]
Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. [2001.12]
Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease. [2001.12]
Effects of sleep on endotoxin-induced host responses in healthy men. [2001.07]
Cytokine changes after a marathon race. [2001.07]
Effect of vitamin supplementation on cytokine response and on muscle damage after strenuous exercise. [2001.06]
Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods. [2001.04]
Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment. [2001.04]
The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis. [2001.04]
The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. [2001.01]
A randomized controlled trial of interleukin-1 receptor antagonist in a rabbit model of ascending infection in pregnancy. [2001]
Interleukin-1 receptor antagonist as an adjunct in the treatment of Haemophilus influenzae otitis media in the chinchilla. [2000.09]
Cytokines and bone loss in a 5-year longitudinal study--hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. [2000.08]
A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. [2000.05]
Cytokine RNA levels in transiliac bone biopsies from healthy early postmenopausal women. [2000.02]
Inflammatory response after laparoscopic and conventional colorectal resections - results of a prospective randomized trial. [2000.01]
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. [1999.08.01]
IL-1ra administration does not improve cardiac function in patients with severe sepsis. [1999.06]
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. [1998.12]
Cytokine production in haemodiafiltration: a multicentre study. [1998.07]
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. [1998.07]
Pro- and anti-inflammatory cytokines in healthy volunteers fed various doses of fish oil for 1 year. [1997.12]
Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. [1997.08.15]
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. [1997.08]
Unopposed interleukin-1 is necessary for increased plasma cytokine and eicosanoid levels to develop in severe sepsis. [1997.07]
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. [1997.07]
Carbohydrate and the cytokine response to 2.5 h of running. [1997.05]
Effects of recombinant soluble type I interleukin-1 receptor on human inflammatory responses to endotoxin. [1996.10.01]
Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. [1996.07]
Effects of granulocyte colony-stimulating factor on plasma cytokine and cytokine receptor levels and on the in vivo host response to endotoxin in healthy men. [1996.02.01]
The protective role of the immunomodulator AS101 against chemotherapy-induced alopecia studies on human and animal models. [1996.01.03]
Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. [1996.01]
Interleukin-1 mediates increased plasma levels of eicosanoids and cytokines in patients with sepsis syndrome. [1995.11]
Interleukin-1 contributes to increased concentrations of soluble tumor necrosis factor receptor type I in sepsis. [1995.08]
Interleukin-1 blockade attenuates mediator release and dysregulation of the hemostatic mechanism during human sepsis. [1995.07]
A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. [1995.05.15]
Interleukin-1 receptor antagonist modifies the changes in vital organs induced by acute necrotizing pancreatitis in a rat experimental model. [1995.05]
Influence of IL-1 receptor blockade on the human response to endotoxemia. [1995.02.01]
Production of interleukin 1 receptor antagonist and interleukin 1 during haemodialysis with cellulose membranes. [1994.09]
Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. [1994.09]
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. [1994.06.15]
Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. [1994.01]
The effect of ultrafiltered dialysate on the cellular content of interleukin-1 receptor antagonist in patients on chronic hemodialysis. [1994]
Other research related to Kineret (Anakinra)
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. [2008.09.03]
Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies. [2008.09]
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. [2008.09]
Interstitial granulomatous drug reaction to anakinra. [2008.08]
Exposition to chickenpox of two children with autoinflammatory syndromes under treatment with anakinra. [2008.06]
The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever. [2008.06]
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. [2008.05.20]
Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra. [2008.05]
The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. [2008.03]
|
